Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

Welcome to OncLive On Air®! I’m your host today, Jax DiEugenio.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Emrelis) in patients with c-MET–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). On May 14, 2025, the FDA granted accelerated approval to telisotuzumab vedotin for the treatment of adult patients with locally advanced or metastatic, nonsquamous NSCLC harboring high c-MET protein overexpression who have received a prior systemic therapy. This decision was based on data from LUMINOSITY. Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

In our exclusive interview, Dr Goldman discussed the evolving role of c-MET as a therapeutic target in NSCLC, the mechanism and rationale behind using telisotuzumab vedotin in MET-overexpressing tumors, and key efficacy outcomes from the nonsquamous, EGFR wild-type cohort of the LUMINOSITY trial. He reviewed how high MET expression, identified through immunohistochemistry, was associated with confirmed objective responses and how this drug compares with existing second-line therapies. Dr Goldman also highlighted telisotuzumab vedotin's safety profile, as well as the agent’s clinical application in patients who have progressed on chemoimmunotherapy.

____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Funding supported by AbbVie. Content independently developed by OncLive.